Get in touch

Dymista^®^ Nasal Spray, suspension \nPrescribing Information

Presentation: Nasal spray suspension. Each gram of suspension contains 1000 micrograms of azelastine hydrochloride and 365 micrograms of fluticasone propionate.
Indications: Relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if treatment with intranasal antihistamine or glucocorticoid alone is not considered sufficient.
Dosage and administration: Adults and Children over the age of 12: One actuation into each nostril twice daily.
Contra-indications: Hypersensitivity to azelastine hydrochloride or fluticasone propionate or any of the other ingredients in this medicine.
Warnings and precautions: Avoid concomitant use with ritonavir. Systemic effects of nasal corticosteroids may occur. Systemic exposure in severe liver disease may be increased. Dymista may result in clinically significant adrenal suppression. Monitor patients who experience changes in vision or have a history of ocular pressure, glaucoma and/or cataract. If adrenal function is impaired, take care when changing medication to Dymista. In patients with infections, recent surgery or injury to nose or mouth, weigh benefits against risks of use. Contains benzalkonium hydrochloride. Experience of use in pregnancy and lactation is limited. Dymista should only be used if the potential benefit justifies the potential risk. Dymista has minor influence on ability to drive and use machines.
Undesirable Effects: Epistaxis, headache, dysgeusia, unpleasant smell, hypersensitivity reactions including anaphylactic reactions, angioedema, bronchospasm, glaucoma, increased intraocular pressure, cataract, septal perforation, growth retardation may be possible in adolescents receiving prolonged treatment and growth should be monitored regularly. Consult the Summary of Product Characteristics for other side effects.
Package Quantities and Basic Price (UK): £18.91 for 23g bottle. Each spray (0.14 g) contains 137 mcg of azelastine hydrochloride and 50 mcg of fluticasone propionate.
Legal category: POM.
Product Licence Holder: Meda Pharmaceuticals Ltd, Skyway House, Parsonage Road, Takeley, Bishops Stortford CM22 6PU. Tel 0845 460 0000.
Marketing Authorisation Number: PL 15142/0258. Date of preparation: April 2013 UK/DYM/13/0007(2).



Adverse events should be reported.
Reporting forms and information can be found at
Adverse events should also be reported to Meda Pharmaceuticals Ltd